FDA approves lixisenatide as AdlyxinTM for the treatment of adults with type 2 diabetes in the U.S.
Approval paves the way for launch by Sanofi of the first Zealand invented product in the U.S. Triggers a $5 million milestone payment from Sanofi FDA is currently reviewing iGlarLixi, the fixed-ratio combination of AdlyxinTM (lixisenatide) and Lantus(r) ( …